Moderna, Inc. (MRNA) Down 5.0% — Should I Scale Back Here?
Key Points
Moderna, Inc. (MRNA) retreated sharply on the NASDAQ, declining 4.95% in the latest session. Shares closed at $52.85, shedding $2.75 from the prior session's close of $55.60. The move extended a pattern of slipping ground rather than building momentum, pushing Moderna further from the higher levels it had recently tested.
Trading activity was notably light as well. Volume registered around 4.0 million shares — well short of the 90-day average of roughly 10.1 million — suggesting the decline unfolded without any broad surge in participation. Even so, the price action was unambiguously negative, with the stock giving back a meaningful chunk of recent gains and continuing to face headwinds near the upper end of its yearly range.
Moderna is currently trading within a wide 52-week band of $22.28 to $59.55, yet it sits roughly 11% below the 52-week high of $59.55 set on 03/04/2026. That gap illustrates how swiftly the stock has cooled from its recent peak, with shares drifting back toward the middle of the range. Compared to peer Health Care names — including Zoetis (ZTS), Alnylam Pharmaceuticals (ALNY), and BeOne Medicines (ONC) — Moderna's latest drop registered as a clear step backward in day-to-day performance.
Why Moderna, Inc. Price is Moving Lower
Moderna's latest bounce has run into fresh headwinds as investors weigh encouraging early-stage melanoma data against a more demanding fundamental backdrop. The recent lift tied to positive Phase 1/2 results and a fast-track designation for mRNA-4359 in combination with pembrolizumab has helped sentiment, but it hasn't resolved deeper concerns over durability and commercialization risk. With shares trading near recent highs, the market appears to be rotating away from "good news" enthusiasm toward a more measured reading of what early clinical signals mean for longer-term revenue and cash flow.
Deteriorating top-line trends are adding to the pressure. Moderna's most recent quarterly revenue fell to $646 million from $973 million in the prior quarter — a sequential decline of -33.6% — while overall revenue growth remains negative at -29.81%. That contraction is difficult to look past given the company's deeply negative profitability profile, which includes a -145.16% profit margin and a loss of -$7.26 per share. Clinical milestones can bolster the investment thesis, but they don't immediately settle the near-term earnings and cash burn debate that so often drives biotech valuations.
A further overhang is the disconnect between current trading levels and Wall Street expectations. Analyst consensus sits at a Hold, yet the average price target in the mid-$30s implies considerable downside from the low-to-mid $50s — a persistent anchor that tends to cap rallies as investors rebalance risk. Even with meaningful partnerships in place through Merck and AstraZeneca, Moderna is competing for capital against other health Care names, keeping a cautious stance well warranted.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D rating with a current recommendation of Sell. The stock was upgraded on 3/12/2026, but that adjustment doesn't change the core conclusion: Moderna, Inc. still ranks as an underperformer on a risk-adjusted basis, and investors would be wise to treat any rebound attempts with caution.
The most pressing issue is that operating momentum and shareholder outcomes have both been disappointing. The Weak Growth Index aligns with a sharp contraction in fundamentals, including revenue growth of -29.81%. Profitability is an equally significant drag — a profit margin of -145.16% goes a long way toward explaining why conventional valuation measures are strained, with a forward P/E of -7.66. Against that backdrop, isolated pockets of progress have not been sufficient to offset the ongoing deterioration in results.
Quality and execution concerns deepen the bearish case. The Very Weak Efficiency Index signals poor returns on capital and limited operating leverage — a material problem for a Health Care company that needs consistent productivity to justify investment risk. The Weak Total Return Index indicates shareholders have not been rewarded for accepting that risk, while the Weak Volatility Index suggests the stock's swings have tended to cut against investors when markets turn unfavorable.
Moderna's balance sheet stands out as a relative bright spot, as reflected in the Excellent Solvency Index, but solvency alone does not make a compelling stock. Within the Health care sector, Moderna's D rating is consistent with other challenged names, including Zoetis Inc. (ZTS, D+) and Alnylam Pharmaceuticals, Inc. (ALNY, D+), and places it in similar company to BeOne Medicines AG (ONC, D-). On the whole, the Weiss Rating reflects a view that the risks continue to outweigh the potential rewards.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company in the Pharmaceuticals, Biotechnology and Life Sciences industry focused on developing messenger RNA (mRNA) medicines for infectious diseases, oncology, and select rare conditions. Headquartered in Cambridge, Massachusetts, the company operates across the United States, Europe, and other international markets. Moderna's approach centers on harnessing mRNA to instruct the body to produce target proteins — a platform strategy with broad disease-area applicability, though one that also ties much of the organization's identity to a relatively narrow technology base.
In respiratory vaccines, Moderna markets Spikevax and is advancing additional mRNA-based candidates spanning COVID-19, RSV, seasonal influenza, combination respiratory vaccines, and pandemic influenza. Beyond respiratory disease, the pipeline reaches into latent viruses such as cytomegalovirus and Epstein-Barr virus, as well as programs targeting HIV and norovirus. Public health-oriented vaccine efforts for Zika, Nipah, and Mpox round out the infectious disease portfolio, alongside bacterial disease work such as Lyme vaccine development.
Outside vaccines, Moderna is pursuing oncology therapeutics — including individualized cancer approaches and immune-modulating modalities such as T-cell engagers and cell therapy enhancers — along with rare disease programs targeting propionic and methylmalonic acidemia and cystic fibrosis. The company maintains an extensive network of alliances spanning Merck & Co., Vertex, immatics, U.S. government-linked research and preparedness agencies, philanthropic organizations, and OpenAI. These relationships can meaningfully expand scientific reach while also adding execution complexity across a diverse mix of partners and priorities.
Investor Outlook
With a Weiss Rating of D (Sell), Moderna, Inc. (MRNA) faces a cautious near-term outlook. Investors may want to watch whether the stock can hold key technical levels and stabilize relative to the broader Health Care group. Keep an eye on upcoming catalysts for signs of improving risk/reward — particularly any shift in sentiment that supports more consistent returns — while remaining mindful of the volatility that can amplify downside moves. For a full ranking of all D-rated Health Care stocks, visit the Weiss Stock Screener.
--